LifeSci Capital Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $35
Express News | Liquidia Corp - Unit Files Patent Infringement Action Against United Therapeutics - SEC Filing
Insider Sale: Chief Business Officer of $LQDA Sells 1,856 Shares
Great Week for Liquidia Corporation (NASDAQ:LQDA) Institutional Investors After Losing 1.5% Over the Previous Year
Needham Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $25
Breaking Down Liquidia: 4 Analysts Share Their Views
Express News | Needham Reiterates Buy on Liquidia, Maintains $25 Price Target
Liquidia Analyst Ratings
BofA Securities Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $22
Liquidia Technologies (LQDA) Receives a Buy From Bank of America Securities
Phaware Launches Special Series of Podcast Episodes Spotlighting the Future of PH-ILD Treatment and Innovation
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
Scotiabank Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $34
Optimistic Buy Rating for Liquidia Technologies Driven by Yutrepia's Regulatory Momentum and Promising Study Results
FDA Accepts Liquidia's NDA Resubmission For Yutrepia, Sets PDUFA Date For May 2025
Express News | Liquidia Corp - FDA Sets Pdufa Goal Date of May 24, 2025 for Yutrepia
Express News | Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for Yutrepia™ (Treprostinil) Inhalation Powder
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference
What Does The Future Hold For Liquidia Corporation (NASDAQ:LQDA)? These Analysts Have Been Cutting Their Estimates
Liquidia Technologies' Earnings Call: Mixed Sentiments and Strategic Growth